stockrow
Saturday 7 November 2026
Export ONCO’s income statement to Excel — free account
Onconetix, Inc.
ONCO Healthcare Biotechnology
Onconetix, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $815,400.00, down 67.7% from fiscal 2024.
- Revenue
- −83.9%
- EPS
- +99.5%
- Free cash flow
- −36.0%
Quarter to June 2026, against a year earlier
6.81
6.26
+1,138.18%
Follow ONCO
Alert me
Onconetix, Inc. (ONCO) P/E ratio
Onconetix, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 0.0× (November 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 0.0× | — |
| Mar 2026 | 0.0× | — |
| Dec 2025 | 0.0× | — |
| Sep 2025 | 0.0× | — |
| 6 more quarters | Free account |
Against its own ten years
Low 0.0×
High 0.0×
Ten-year median
0.0×
Current reading's percentile
100
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| PBLA Panbela Therapeutics Inc. compare | n/m |
| ERNA Ernexa Therapeutics Inc. compare | n/m |
| ONCO Onconetix, Inc. | n/m |
| GRI GRI Bio, Inc. compare | n/m |
| ADXN Addex Therapeutics Ltd. Sponsored ADR compare | n/m |
| LIPO Lipella Pharmaceuticals Inc. compare | n/m |
| TRAW Traws Pharma, Inc. compare | n/m |
| SXTP 60 Degrees Pharmaceuticals Inc. compare | n/m |
| MBIO Mustang Bio, Inc. compare | n/m |
| Biotechnology industry median | 10.6× |
| Healthcare sector median | 24.5× |
| Market median | 17.8× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)